Die Seroepidemiologie der Hepatitis A, B und C in Deutschland

Poethko‐Müller, Christina; Zimmermann, Ruth; Hamouda, Osamah; Faber, Mirko; Stark, Klaus; Roß, R. Stefan; Thamm, Michael

doi:10.1007/s00103-013-1673-x

Cited by 123 publications

(56 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the prevalence of positive donors was far too low, notably in the biggest donor groups tested: only 2 of 21,181 blood donors had replicative hepatitis B or hepatitis C, and these were congruently identified by the Ultrio Elite Assay and serological screening tests. Moreover, the anti-HBc prevalence - and hence the risk for occult hepatitis B - was very low, 0.34% (74 of 21,181) in the blood donor group compared to 5.1% in the average German population [9]. Therefore, not a single case of occult hepatitis B (low-level HBV DNAemia without HBsAg detection) was found in the blood donor group.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, tissue donors with risk factors for parenterally transmitted virus infections cannot be excluded sufficiently from the tissue donor pool, resulting in a significantly higher prevalence of anti-HBc (11.7%, 115 of 984) compared to the blood donor group (p < 0.0001, chi square test). Anti-HBc prevalence of tissue donors was even higher than in the average German population (5.1%) [9]. Two (1.7%, donors #4 and 5) of these 115 anti-HBc-positive tissue donors had an occult hepatitis in spite of anti-HBs titers > 10 IU/ml.…”

Section: Discussionmentioning

confidence: 99%

“…ID-NAT for HBV DNA could reduce the risk of HBV transmission both in case of occult hepatitis B (low-level carriers) and during the serological window period [9,10]. MP-NAT for HBV DNA is prone to fail in occult hepatitis B due to its higher LOD, and its effect on window period transmissions is small due to the high sensitivity of HBsAg tests [11,12].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors

Heim¹

2016

Transfus Med Hemother

View full text Add to dashboard Cite

Background: The performance of the multiplex Procleix Ultrio Elite assay as individual donor nucleic acid test (ID-NAT) for the detection of HIV-1, HIV-2, HCV, and HBV was evaluated in a retrospective, single center study. Methods: ID-NAT results of 21,181 blood donors, 984 tissue donors, 293 hematopoietic stem cell donors and 4 organ donors were reviewed in synopsis with results of serological screening and additional discriminatory and repetitive NAT in case of positive donors. Results: Specificity of the initial Procleix Ultrio Elite assay was 99.98% and after discriminatory testing 100.00%. Initially invalid results were observed in 75 of 21,181 blood donors (0.35%) but 16 of 984 tissue donors (1.62%, p < 0.001) which included non-heart-beating (‘cadaveric') donors. All these had valid negative ID-NAT results after repeated testing or testing of 1:5 diluted specimens in case of tissue donors. Occult hepatitis B (defined here as HBV DNAemia without HBsAg detection) was demonstrated by ID-NAT in two anti-HBc-positive tissue donors and suspected in two other tissue donors, where a definite diagnosis was not achieved due to the insufficient sample volumes available. Conclusion: The Procleix Ultrio Elite assay proved to be specific, robust and rapid. Therefore, routine ID-NAT may also be feasible for organ and granulocyte donors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors

Heim¹

2016

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…Nach Aufklä-rung in der jeweiligen Landessprache wurde jedem Flüchtling, der sich aufgrund von akuten Beschwerden in ärzt-liche Behandlung begab, im Rahmen einer ersten Routineversorgung eine Blutentnahme zur Testung auf sexuell übertragbare Erkrankungen wie HIV und Syphilis [14] und impfpräventable Erkrankungen wie Masern, Mumps, Rö-teln, Varizellen inklusive einem Test auf eine Hepatitis-B-Virusinfektion angeboten. Dies erfolgte, um gemäß Leitlinie der deutschen Gesellschaft für Verdauungsund Stoffwechselkrankheiten (DGVS) [15] (5,(9)(10)(11)(12)(13)4) Männlich 215 (11,(9)(10)(11)(12)(13)(14)(15)(16)9) Männlich 608 Bei N = 239 Flüchtlingen lagen Daten zu anti-HBs-Antikörperkonzentra-tionen vor. 62,4 % (n = 161) der Flüchtlin-ge besaßen keine Immunität gegen Hepatitis B (anti-HBs und anti-HBc negativ).…”

Section: Methodenunclassified

“…Anhand bereits erhobener Daten in der Vergangenheit zeigte sich im Vergleich zur Gesamtprävalenz von 0,4 % positiven HBsAg-Trägern in Deutschland erwartungsgemäß eine höhere Prävalenz der ankommenden Flüchtlinge in Deutschland von 2,3 % [4].…”

Section: Diskussionunclassified

Aktuelle Seroprävalenz, Impfstatus und prädiktiver Wert der Leberenzyme für Hepatitis B bei Flüchtlingen in Deutschland

Hampel

Solbach

Cornberg

et al. 2016

Bundesgesundheitsbl

View full text Add to dashboard Cite

show abstract

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal

Sarrazin

Boesecke

Golsabahi-Broclawski³

et al. 2021

Health Science Reports

View full text Add to dashboard Cite

Hepatitis C virus (HCV) affects over 70 million people globally, with an estimated 399 000 HCV‐related deaths in 2016. The World Health Organization (WHO) has set a goal to eliminate HCV by 2030. Despite the availability of direct‐acting antivirals—highly effective and well‐tolerated therapies for HCV—many patients infected with HCV in Germany have not initiated treatment, including a majority of those who are aware of their positive diagnosis. Barriers to screening, diagnosis, and treatment are major factors taking many countries off track for HCV elimination by 2030. Identifying country‐specific barriers and challenges, particularly in at‐risk populations such as people who inject drugs or men who have sex with men, has the potential to create tailored programs and strategies to increase access to screening or treatment and engage at‐risk populations. This review aims to report the current steps toward HCV elimination in Germany, the country‐specific barriers and challenges that will potentially prevent reaching the 2030 HCV elimination goal and describe good practice examples to overcome these barriers.

show abstract

Die Seroepidemiologie der Hepatitis A, B und C in Deutschland

Cited by 123 publications

References 21 publications

Evaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors

Evaluation of the Procleix Ultrio Elite Assay and the Panther-System for Individual NAT Screening of Blood, Hematopoietic Stem Cell, Tissue and Organ Donors

Aktuelle Seroprävalenz, Impfstatus und prädiktiver Wert der Leberenzyme für Hepatitis B bei Flüchtlingen in Deutschland

Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal

Contact Info

Product

Resources

About